Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors

If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.

You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.

Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(12 hours of CE)  $140.00

In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.

Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT

The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.

More Information About Traineeship

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Download

1.  The newer oral anticoagulants work by:

1. Indirectly inhibiting factor VIII
2. Directly inhibiting factor IIa or Xa
3. Causing the breakdown of fibrin
4. Decreasing the production of factor II

2. p-Glycoprotein inhibition leads to

1. Increased substrate serum levels
2. Decreased substrate serum levels
3. Increased metabolism of substrate
4. No effect

3. Which agent was shown to be superior to warfarin in both safety and efficacy in atrial fibrillation

1. Dabigatran
2. Rivaroxaban
3. Apixaban
4. None of the above

4. There is no evidence to suggest that pharmacists can impact the care of patients receiving the new oral agents.

1. True
2. False

5. For the treatment of an acute venous thromboembolism, initial parenteral anticoagulants are not needed for therapy with:

1. Dabigatran or Rivaroxaban
2. Rivaroxaban or Apixaban
3. Apixaban or Edoxaban
4. A parenteral anticoagulant is always needed for at least the first week.

6. This drug should not be placed in a pill box

1. Dabigatran
2. Rivaroxaban
3. Apixaban
4. Edoxaban

7. What type of patient would be considered a good candidate to for DOAC therapy?

1. Documented warfarin allergy
2. History of poor INR control on warfarin despite good compliance
3. Considerable barriers to routine monitoring, such as physical or transportation issues
4. Document and confirmed warfarin failure such as an ischemic stroke while consistently therapeutic on warfarin
5. All of the above

8. To switch a patient from subcutaneously LMWH to a DOAC, you would recommend to discontinue the LMWH and then…

1. begin the new agent 3 days later if the patient has normal renal function
2. begin the new agent when the patient’s PTT and INR are sub-therapeutic
3. bridge with LMWH and the DOAC for 24 hours
4. begin the new agent when the next dose of LMWH would be due

9. Which of the following DOACs’ bioavailability substantially increases when it is taken with food (largest meal of the day)?

1. Edoxaban
2. Rivaroxaban
3. Dabigatran
4. Apixaban

10. Prior to initiating a DOAC, the patient should be evaluated for which the following?

1. Renal Clearance
2.  Appropriate and approved indication for the specific DOAC agent
3. Review of patient medication profile to check for potentially significant drug-drug interactions
4. Adequate insurance coverage or prescription assistance before starting the DOAC agent
5. All of the above

Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour

Anticoagulation Management Pearls - 1 hour

Direct Oral Anticoagulants and Factor IIa and Xa Inhibitors – 1 hour

Laboratory Monitoring of Anticoagulation – 1 hour

Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours

Developing an Anticoagulation Clinic – 1.0 hour

Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour

Risk Management in Anticoagulation – 1 hour

Perioperative Management of Warfarin Interruption – 1 hour

Hypercoagulable States – 1 hour

Challenging Topics in Anticoagulation – 1 hour

Available Strategies to Reverse Anticoagulation Medications - 1 hour

Case Studies in Drug Interactions with Anticoagulation Therapy – 1 hour